Andexxa (Ondexxya) Market Report 2026

Andexxa (Ondexxya) Market Overview

• The Andexxa (Ondexxya) market growth in the historic period has been driven by widespread use of factor xa inhibitors, emergency bleeding incidents • Market expansion is supported by growth in cardiovascular disease prevalence, increased anticoagulant prescriptions • Growth Driver: Growing Prevalence Of Bleeding Disorders Fuels Demand In The Andexxa (Ondexxya) Market • Market Trend: Innovative Advancements In The Andexxa (Ondexxya) Market • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Andexxa (Ondexxya) Market?

Andexxa (Ondexxya) is a reversal agent used to counteract the anticoagulant effects of certain blood thinners, specifically Factor Xa inhibitors such as rivaroxaban (Xarelto) and apixaban (Eliquis). It is used in cases of life-threatening or uncontrolled bleeding or when immediate reversal of anticoagulation is necessary. The main types of indications for andexxa (ondexxya) include reversal of bleeding caused by factor Xa inhibitors, acute major bleeding events, and emergency surgery or procedures. Factor Xa inhibitors are anticoagulants that prevent blood clotting, but in cases of excessive bleeding, their effects may need to be reversed. It is distributed through various channels, including hospital pharmacies and specialty pharmacies, and is used by adults, geriatrics, and pediatrics.

What Is The Andexxa (Ondexxya) Market Growth Forecast?

The growth in the forecast period can be attributed to growth in cardiovascular disease prevalence, increased anticoagulant prescriptions, trauma care expansion, improved emergency protocols, rising surgical interventions. Major trends in the forecast period include rising need for anticoagulant reversal, growth in emergency bleeding management, hospital centered critical care therapies, increased use of factor xa inhibitors, focus on rapid hemostasis solutions.

What Are The Drivers Of The Andexxa (Ondexxya) Market?

The increase in bleeding disorders is expected to propel the growth of the andexxa (ondexxya) market going forward. Bleeding disorders refer to a group of medical conditions that impair the blood's ability to clot properly, leading to excessive or prolonged bleeding. The increase in bleeding disorders can be due to improved diagnosis, increased awareness, genetic factors, and the aging population, which may lead to a higher recognition and detection of these conditions. Andexxa (Ondexxya) is required for bleeding disorders because it rapidly reverses the anticoagulant effects of factor Xa inhibitors, preventing life-threatening bleeding in emergency situations. For instance, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, there were 2,797 patients living with von Willebrand disease (VWD) in 2023–2024, up from 2,669 patients in 2022–2023. Therefore, the increase in bleeding disorders is driving the growth of the andexxa (ondexxya) industry. The increasing geriatric population is expected to propel the growth of the andexxa (ondexxya) market going forward. The geriatric population refers to people aged 65 and older, often facing age-related health challenges such as chronic diseases, cognitive decline, and mobility issues. The geriatric population is growing globally due to increased life expectancy and improvements in healthcare. Andexxa (Ondexxya) is useful for the geriatric population as it helps reverse bleeding caused by blood thinners, which older adults are more likely to use due to conditions such as atrial fibrillation. For instance, in October 2022, according to a report published by the World Health Organization (WHO), a Switzerland-based agency responsible for international public health, one in six people is expected to be 60 or older by the year 2030, in the entire world. By 2050, there will be 2.1 billion people worldwide who are 60 years old or older. Therefore, the increasing geriatric population is driving the growth of the andexxa (ondexxya) industry.

Key Players In The Global Andexxa (Ondexxya) Market

Major companies operating in the andexxa (ondexxya) market are AstraZeneca Plc

Global Andexxa (Ondexxya) Market Trends and Insights

Major companies operating in the Andexxa market are focusing on developing advanced anticoagulant reversal therapies to enhance patient safety in critical bleeding events. Reversal therapy is a targeted treatment that neutralizes the effects of anticoagulant drugs, restoring normal clotting function rapidly and reducing the risk of fatal bleeding. For instance, in January 2024, AstraZeneca India received CDSCO approval to import and market andexanet alfa for life-threatening or refractory bleeding caused by Factor Xa inhibitors such as apixaban and rivaroxaban. This newly approved treatment features an initial intravenous bolus over 15–30 minutes followed by a 2-hour infusion. Andexanet alfa has demonstrated efficacy and safety in clinical studies of major bleeding, it allows early restart of anticoagulation after an event, it is well tolerated, and it addresses a critical unmet need in patients on novel oral anticoagulants.

What Defines the Andexxa (Ondexxya) Market?

The andexxa (ondexxya) market consists of sales of anticoagulant reversal agents, factor xa inhibitors, hemostatic agents and blood clotting factor concentrates. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Andexxa (Ondexxya) Market Report 2026?

The andexxa (ondexxya) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the andexxa (ondexxya) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.